Autologous Bone Marrow-Derived Mononuclear Cell Transplantation in Accelerating Tissue Expansion and Skin Regeneration
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01209611|
Recruitment Status : Unknown
Verified April 2014 by Qing-Feng Li, Shanghai Jiao Tong University School of Medicine.
Recruitment status was: Recruiting
First Posted : September 27, 2010
Last Update Posted : April 22, 2014
|Condition or disease||Intervention/treatment||Phase|
|Tissue Expansion; Skin Regeneration; Reconstruction; Bone Marrow Mononuclear Cells||Procedure: Autologous bone marrow mononuclear cells Procedure: Placebo||Phase 1 Phase 2|
Reconstruction of large scale skin defect is a challenge to clinical surgeons. Soft tissue expansion has won wide attention in recent years as it promotes skin regeneration with perfectly matched tissue. However, some patients with poor skin regenerative ability would suffer from skin flap over-thinned and even necrosis under the continuous stretching by silicone expander. Although, on some occasions, decelerating the expander inflation process could reduce the incidence of necrosis, this prolonged therapy circle is to be accompanied with increased complications, including infection and expander rupture, as well as the increased economic expenses by the longer hospitalization. This study is to observe the effects of autologous bone marrow mononuclear cell transplantation on accelerating skin regeneration and promoting tissue expansion process.
Patients aged between 18 to 60 years old who appear with deteriorated expanded skin will be enrolled and randomized into two groups, named as the experimental group and the control group. Patients from the experimental group will have a bone marrow aspiration and intradermal mononuclear cells transplantation. On the other side, Patients from the control group will have saline injection.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||30 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Phase 1/2 Study of Autologous Bone Marrow-Derived Mononuclear Cell Transplantation in Accelerating Soft Tissue Expansion|
|Study Start Date :||September 2010|
|Actual Primary Completion Date :||October 2013|
|Estimated Study Completion Date :||December 2014|
Experimental: Autologous bone marrow mononuclear cells
Patients received autologous MNC transplantation. Bone marrow aspirates are harvested from the anterior iliac crest of the patients under general or local anesthesia. MNCs are isolated by density gradient centrifugation. The cell suspension was adjusted to a final volume of 6-20 ml with saline. The cell suspension was injected into expanded skin intradermally via a 27-gauge needle (approximately 0.5-1×10^6 cells/cm2).
Procedure: Autologous bone marrow mononuclear cells
Autologous bone marrow-derived mononuclear cells, after isolated by density gradient centrifugation from bone marrow aspiration and resuspended in saline, will be transplanted subcutaneously to expanded skin. The number of infused cells will be 1x10e6/cm2.
Placebo Comparator: Saline
Patient has intradermally and subcutaneously injection of saline.
Patients will have mimical bone marrow aspiration under local anesthesia following with saline injection to expanded skin.
- Occurence of major adverse events [ Time Frame: Up to approximately 24 months after study start ]Including expanded flap ischaemia, necrosis, fluidify, infection, and all other adverse events
- To measure inflation volume of the silicone expander [ Time Frame: baseline, 4 weeks and 8 weeks post treatment ]
- To measure the size of expanded flap [ Time Frame: baseline and 8 weeks post treatment ]
- To measure the texture of expanded flap [ Time Frame: 4 weeks and 8 weeks post treatment ]
- To measure expanded skin thickness by ultrasound scanning [ Time Frame: baseline, 4 weeks and 8 weeks post treatment ]
- Laboratory examinations including routine blood test, liver function and renal function [ Time Frame: baseline and 8 weeks post stem cell transplantation ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01209611
|Contact: Qingfeng Li, MD, PhD||0086 21 email@example.com|
|Contact: Shuangbai Zhou, MD||0086 firstname.lastname@example.org|
|Shanghai Ninth People's Hospital, Affliated to Shanghai Jiao Tong University School of Medicine||Recruiting|
|Shanghai, Shanghai, China, 200011|
|Contact: Qingfeng Li, MD, PhD 0086 21 63089567 email@example.com|
|Contact: Shuangbai Zhou, MD 0086 13482514585 firstname.lastname@example.org|
|Principal Investigator: Qingfeng Li, MD, PhD|
|Sub-Investigator: Shuangbai Zhou, MD|
|Sub-Investigator: Tao Zan, MD, PhD|
|Study Director:||Qingfeng Li, MD, PhD||Shanghai Ninth People's Hospital Affiliated to Shanghai Jiaotong University School of Medicine|